The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his insights on what to look out for from Day 5 of ESMO 2021.
Dr Morgan mentions results from studies including IMpower010, VOICE and REACH-GORTEC.
You can watch Dr Morgan's previous roundup here.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
Search and follow #OncoAlertTopTweet to stay up to date.
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert round up July 28th to August 3rd, 2023
The advantages of IORT for early breast cancer treatment
